Veeva SystemsWBO:VEEV +5.25%84 FCF Margin % is 127.65% as of Apr. 2026, which is 235% above its 10-year median of 38.10. GuruFocus rates WBO:VEEV with a GF Score™ of 84/100 and a GF Value™ of €246.73 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 669 Healthcare Providers & Services companies, Veeva Systems ranks better than 98.8% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Veeva Systems's Free Cash Flow for the
three
months ended in Apr. 2026 was €964 Mil. Veeva Systems's Revenue for the
three
months ended in Apr. 2026 was €755 Mil. Therefore, Veeva Systems's FCF Margin % for the quarter that ended in Apr. 2026 was 127.65%.
The historical rank and industry rank for Veeva Systems's FCF Margin % or its related term are showing as below:
WBO:VEEV'
s FCF Margin % Range Over the Past 10 Years
Min: 24.79 Med: 38.1 Max: 50.17
Current: 50.17
During the past 13 years, the highest FCF Margin % of Veeva Systems was 50.17%. The lowest was 24.79%. And the median was 38.10%.
WBO:VEEV's FCF Margin % is ranked better than 98.8% of 669
companies
in the Healthcare Providers & Services industry
Industry Median: 3.39
vs WBO:VEEV: 50.17
Veeva Systems FCF Margin % Related Terms
Veeva Systems FCF Margin % Historical Data
* Premium members only.
The historical data trend for Veeva Systems's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:VEEV vs BTSG, TEM, HQY: FCF Margin % Comparison
For the Health Information Services subindustry, Veeva Systems's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veeva Systems FCF Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Veeva Systems's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Veeva Systems's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veeva Systems (WBO:VEEV) has a FCF Margin % of 127.65% as of Apr. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Veeva Systems and its competitors. This is 235% above median its historical median of 38.10. Over the past decade, Veeva Systems' FCF Margin % has ranged from 24.79 to 50.17. According to the industry distribution chart, Veeva Systems ranks #8 out of 669 companies in the Healthcare Providers & Services industry, placing it in the top 1.2%.
Is Veeva Systems' FCF Margin % too high?
Veeva Systems' current FCF Margin % of 127.65% is 235% above median its 10-year median of 38.10. Over the past 10 years, this metric has ranged from a low of 24.79 to a high of 50.17. The Healthcare Providers & Services industry median FCF Margin % is 3.39. Veeva Systems' value of 127.65% is 3665.5% above this industry median. Based on the distribution chart, Veeva Systems ranks #8 out of 669 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Veeva Systems has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Veeva Systems' FCF Margin % compare to BTSG and TEM?
According to the Healthcare Providers & Services industry distribution chart, Veeva Systems ranks #8 out of 669 companies for FCF Margin %. This places Veeva Systems in the top 1% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 3.39. Veeva Systems' value of 127.65% is 3665.5% above this benchmark. Historically, Veeva Systems' own FCF Margin % has ranged from 24.79 to 50.17 over the past decade. While the company's 10-year median is 38.10 vs. the industry median of 3.39, Veeva Systems has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Healthcare Providers & Services company?
The median FCF Margin % among Healthcare Providers & Services companies is 3.39, based on 669 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Veeva Systems's current FCF Margin % of 127.65% is 3665.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Veeva Systems and its competitors. For the Healthcare Providers & Services industry, the median FCF Margin % is 3.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veeva Systems's current FCF Margin % is 127.65%, which is 235% above median its own 10-year median of 38.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veeva Systems stock overvalued right now?
Based on GuruFocus' analysis, Veeva Systems (WBO:VEEV) is currently considered Significantly Undervalued. The stock's GF Value™ is €246.73, compared to a current price of €148.25 — trading 39.9% below its estimated fair value. The current FCF Margin % is 127.65%, which is 235% above median its 10-year median of 38.10 and 3665.5% above the Healthcare Providers & Services industry median of 3.39. Veeva Systems' overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Veeva Systems (WBO:VEEV), the current FCF Margin % is 127.65% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Veeva Systems (WBO:VEEV) Overvalued in 2026?
Based on GuruFocus' analysis, Veeva Systems stock appears to be undervalued.
The current stock price of €148.25 is trading 39.9% below its estimated GF Value™ of €246.73.
GuruFocus considers Veeva Systems to be Significantly Undervalued.
Key valuation signals for WBO:VEEV:
FCF Margin %: 127.65% (235% above median its 10-year median of 38.10)
GF Value™: €246.73 vs. price of €148.25 (39.9% below fair value)
Industry Position: 3665.5% above the Healthcare Providers & Services median (#8 of 669)
No single metric tells the full story. See the WBO:VEEV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
84GF Score
Get the complete analysis for WBO:VEEV
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:VEEV has been successfully added to your 
